We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The marketing of products — particularly
medical devices — for purposes for which they were not developed,
tested or intended is coming under increased scrutiny by the FDA and
Congress.
Sen. Herb Kohl (D-Wis.) proposed creating
a national registry to disclose gifts physicians receive from the
pharmaceutical industry during a Senate Special Committee on Aging
hearing.
Per capita healthcare spending in Asia is
expected to increase by almost 64 percent by 2010, expanding markets
for medical devicemakers, according to a new report from Kalorama
Information.
Pharmaceutical advertising increasingly
includes unsubstantiated claims about the safety and efficacy of drug
products while downplaying or even failing to completely discuss the
risks associated with taking them, Thomas Abrams, the director of the
FDA’s Division of Drug Marketing, Advertising and Communication
(DDMAC), said.
An aging population, increasingly
consumer-directed healthcare, Medicare Part D and a surge in generic
drug availability in key therapeutic areas are the main drivers of
growth in the generic market, according to healthcare industry experts.
In its recent “2007 National Trade
Estimate Report for India,” PhRMA objected to India’s plans to impose
price controls on 354 more drugs, in addition to the 74 that currently
have price controls.
Industry groups say the Patent Reform Act
of 2007 threatens to “devastate life sciences investment” by weakening
the patent system for medical devicemakers.